FTD/TPI is an anti-tumor medication administered orally that consists of trifluridine (a nucleoside analogue), and tipiracil (a thymidine phosphorylase inhibitor), and is registered for mCRC refractory to standard regimens in over 93 countries (Bachet et al., 2020). This evidence concerns the gene TYMP and neoplasm.